Stryker (NYSE:SYK) Issues Earnings Results

Stryker (NYSE:SYK) posted its earnings results on Thursday. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07, FiscalAI reports. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the prior year, the company posted $4.01 earnings per share. Stryker’s revenue for the quarter was up 11.4% compared to the same quarter last year.

Here are the key takeaways from Stryker’s conference call:

• Stryker reported strong 2025 results with organic sales up ~10.3% for the year, Q4 organic growth of 11%, more than $25 billion in sales, adjusted EPS growth (~11.8% to $13.63), and 2026 guidance of 8–9.5% organic growth and EPS of $14.90–$15.10.
• Robotics are a major tailwind — the company now has >3,000 Mako systems with record installs and high utilization (over two‑thirds of U.S. knees), plus initial cases on the new handheld Mako RPS, supporting future implant and capital revenue.
• Broad product momentum — MedSurg/Neurotechnology, Instruments (U.S. organic +19.1%), Endoscopy, and Medical each posted strong growth, aided by new launches (e.g., Triathlon Gold, 1788 platform) and favorable ASC/capital demand.
• Tariff headwinds remain material — Stryker expects approximately $400 million of full‑year tariff impact in 2026 (including a ~$200 million incremental hit in H1), which will pressure margins despite ongoing mitigation efforts.
• Vascular dynamics are mixed — hemorrhagic products and Inari/peripheral vascular showed strong procedural growth, but ischemic business faced competitive pressure and Q4 stocking/disruption (expected to be minimal in Q1), creating near‑term uncertainty.

Stryker Stock Down 1.0%

SYK opened at $354.39 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker has a one year low of $329.16 and a one year high of $404.87. The business’s 50-day simple moving average is $359.38 and its 200-day simple moving average is $371.95. The stock has a market capitalization of $135.52 billion, a P/E ratio of 46.57, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be paid a $0.88 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, December 31st. Stryker’s payout ratio is currently 46.25%.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top‑line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double‑digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell‑side pressure or signal near‑term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one‑time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer‑term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Truist Financial cut their price target on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Sanford C. Bernstein boosted their price objective on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. BTIG Research reaffirmed a “buy” rating and set a $410.00 target price on shares of Stryker in a report on Friday, November 14th. Finally, Wells Fargo & Company increased their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $425.94.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 522,118 shares of company stock worth $185,381,932 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its holdings in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Invesco Ltd. grew its stake in Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after buying an additional 80,536 shares during the period. Two Sigma Investments LP boosted its position in Stryker by 15.4% during the 3rd quarter. Two Sigma Investments LP now owns 554,353 shares of the medical technology company’s stock worth $204,928,000 after purchasing an additional 73,810 shares during the period. California State Teachers Retirement System grew its stake in shares of Stryker by 0.9% in the third quarter. California State Teachers Retirement System now owns 551,248 shares of the medical technology company’s stock valued at $203,780,000 after buying an additional 5,182 shares in the last quarter. Finally, Credit Agricole S A acquired a new stake in Stryker in the third quarter valued at approximately $194,045,000. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.